Embecta raises FY2025 adjusted EBITDA margin guidance to 37% amid cost-cutting and debt reduction focus
Adjusted EBITDA margin increased to 37.2% from 25.2% in Q4 2024, driven by cost reductions and operational improvements. Management's tone shifted positively, highlighting stronger-than-expected ...
Embecta Corp. Reports First Quarter Fiscal 2025 Financial Results
Embecta Corp. ("embecta" or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three month period ...
Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business
Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions ...
drugdeliverybusiness13u
Embecta stock rises on Street-beating Q1, patch pump continuation remains on track
Embecta (Nasdaq:EMBC) shares ticked up before hours today on first-quarter results that came in ahead of the consensus forecast.
Medtronic: Undervalued But Underperforming - Why Innovation Isn't Enough To Lift The Stock
Medtronic's stock lags peers due to growth challenges in the diabetes and hypertension markets. See why we recommend a sell ...